Under the terms of the agreement, OncoGenex is entitled to receive royalty payments from future Tocosol Paclitaxel sales and a percentage of sub-licensing royalty and milestone payments received
Receipt of $15 million was triggered by acceptance of the Remoxy new drug application by the FDA. Receipt of an additional $5 million was triggered by FDA’s acceptance
The priority review status provides for a review period of six months from the date of submission. The Embeda capsule new drug application was submitted on June 30,
Under the terms of the agreement, the payment was triggered by the initiation of a Phase I clinical study by Novartis of QAX935. QAX935 is a novel agonist
Oncothyreon expects to begin marketing the offering in the second week of September, 2008. The per share offering price to the public will be determined based on market
In connection with the agreement, Purdue has agreed to grant Mallinckrodt a royalty-bearing license to sell limited quantities of generic versions of 10mg, 20mg, 40mg, and 80mg extended-release
Study 301 is a multinational, randomized, placebo-controlled, induction-design Phase III trial evaluating up to 118 patients. The trial is approximately four weeks in duration and includes an initial
This multi-center, double-blind, randomized and placebo-controlled clinical trial compares the safety and efficacy of Prulifloxacin versus placebo in adult travelers suffering from acute bacterial gastroenteritis. Clinical trial sites
Mr Phillips has served as a member of the company’s board of directors since 2000, and was the chair of the nominating and corporate governance committee and a
Dexamethasone sodium phosphate injection is indicated to treat various conditions such as endocrine disorders, arthritis, blood disorders, dermatologic diseases, severe allergic reactions, eye diseases, certain cancers, gastrointestinal diseases
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.